• Careers
  • News and Events
  • Investors
  • PAREXEL Japan
  •  
Locate a Pharmaceutical Consulting Partner
Pharmaceutical Development Library
PAREXEL Career Center
PAREXEL - Be an Investigator
Subscribe to the PAREXEL Podcast Series

Four growth-driving partnership activities, part 2

Designing strategic partnerships for results

To gain greatest advantage, pharma companies and their partners need to define and design optimal relationships. With Josh Schultz, Vice President and Strategic Account Leader at PAREXEL, and Cynthia Crooks-Garcia, Insights 1 to 1 Host. Part 2 of 2 (00:15:25)

About Josh Schultz, Vice President and Strategic Account Leader at PAREXEL. Josh focuses on developing and leading innovative relationships with key pharmaceutical companies. He has held a number of roles within PAREXEL including building a group dedicated to efficient operational design and launch of clinical studies (START) and another focused on pharmacovigilance.

 Josh Schultz
More Podcasts...

Strategic partnerships: New frontiers of strategic advantage

Faced with continuing financial and competitive pressures, many biopharmaceutical companies are moving beyond the traditional, narrowly focused relationships with their CROs and exploring new types of strategic partnerships designed to deliver project oversight cost reductions and time savings. In this Insights 1 to 1 podcast, Dr. Mark Goldberg, Chief Operating Officer of PAREXEL, discusses how achieving those goals requires a new, long-term, partnership paradigm characterized by deeper and more complex relationships between biopharmaceutical companies and CROs. With Cynthia Crooks-Garcia, Insights 1 to 1 Host. (00:23:13)

Dr. Mark Goldberg is Chief Operating Officer of PAREXEL. As COO, Dr. Goldberg has been on PAREXEL's executive management team for more than 14 years. His combined medical, technical, and clinical research expertise positions him well to help biopharmaceutical leaders understand and navigate the complexities of product development and commercialization. Today, Dr. Goldberg is focused on strengthening partnerships and leveraging PAREXEL’s leadership role in the convergence of services and technology in support of clinical research.

 Dr. Mark Goldberg

Leveraging the transition from clinical to commercial

Fresh thinking that unlocks strategic advantage

Increasing regulatory scrutiny, greater patient and physician expectations, and competition in the marketplace are putting pressure on pharmaceutical companies to develop new strategic plans for the transition from clinical research to commercialization, and for post-marketing research. In this Insights 1 to 1 podcast, Neal Mantick, Senior Director of Global Observational Research at PAREXEL, discusses perspectives and practices that make the most of these critical steps.

For more information on observational research, click here.

(00:11:20)

Neal Mantick is Senior Director of Global Observational Research at PAREXEL. Neal has directed a wide variety of post-marketing clinical research and commercialization programs, such as patient registries, for groundbreaking biopharmaceutical drug products and medical devices for patients with unmet medical needs. He is dedicated to expanding physician and patient access to novel health solutions and technologies.

 Neal Mantick

The promise of the eCRO

Explore the possibilities of the services and technology convergence

In recent years clinical trial technology and services have begun to converge, creating a new kind of contract research organization, the eCRO. In this Insights 1 to 1 podcast, George Hunnewell, Vice President of Post Sales Operations at Perceptive Informatics, discusses the competitive advantages of partnership with this new kind of CRO. (00:07:08)

George Hunnewell is Vice President of Post Sales Operations at Perceptive Informatics, a PAREXEL Company. George is responsible for optimizing operational business processes and establishing process improvement mechanisms. George was part of the executive team that created Perceptive in 2000 as the clinical technology subsidiary of PAREXEL.

 George Hunnewell

The three core benefits of eClinical technologies

New levers to improve clinical trial decisions and operations

Pharmaceutical companies are facing new pressures in the development of new product. Global trials are inherently complex, regulatory expectations are changing, and process and technology innovations are adopted slowly. In this Insights 1 to 1 podcast, Dr. Barbara Tardiff discusses the levers pharma companies have for improving their clinical trial decision-making and operations. With Cynthia Crooks-Garcia, Insights 1 to 1 Host. (00:17:39)

Dr. Barbara Tardiff is Vice President, eClinical, at Perceptive Informatics, a PAREXEL Company.
Barbara is an expert in the integration, deployment, and evaluation of biomedical data, and has participated in a broad range of scientific and operational development activities. Dr. Tardiff has held executive positions in the pharmaceutical industry overseeing biomedical and clinical information systems, and is Board certified in pediatrics and anesthesiology.

 Dr. Barbara Tardiff

Four growth-driving partnership activities, part 1

Realizing new value through strategic partnerships

To gain the greatest advantage, pharma companies and their partners need to define and design optimal relationships. With Josh Schultz, Vice President and Strategic Account Leader at PAREXEL, and Cynthia Crooks-Garcia, Insights 1 to 1 Host. (part 1 of 2) (00:16:38)

Josh Schultz is Corporate Vice President and Strategic Account Leader at PAREXEL. Josh focuses on developing and leading innovative relationships with key pharmaceutical companies. He successfully built a number of operations within PAREXEL including building a group dedicated to efficient operational design and launch of clinical studies (START) and another focused on pharmacovigilance.

 Josh Schultz